This is a randomized, double-blind, placebo-controlled, phase 2 study. Subjects will include
postmenopausal women with confirmed HR-positive, locally advanced or metastatic breast
cancer, who have disease progression during or within 12 months after completing prior
adjuvant endocrine therapy or during the first prior endocrine therapy for metastatic
disease.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Research Site, Dijon 21079, France
Research Site, Le Mans 72000, France
Research Site, Lyon 69008, France
Research Site, Montpellier Cedex 5 34298, France
Research Site, Nice Cedex 2 06182, France
Research Site, Paris Cedex 5 75248, France
Research Site, Reims Cedex 51056, France
Research Site, Saint Herblain 44800, France
Research Site, Frankfurt 60590, Germany
Research Site, Frankfurt 65929, Germany
Research Site, Hannover 30177, Germany
Research Site, München 80637, Germany
Research Site, Dublin 4, Ireland
Research Site, Dublin 8, Ireland
Research Site, Madrid 28040, Spain
Research Site, Chur 7000, Switzerland
Research Site, Luzern 16 6000, Switzerland
Research Site, Zurich 8032, Switzerland
Research Site, Derby DE22 3DT, United Kingdom
Research Site, London W6 8RF, United Kingdom
Research Site, Manchester M20 4BX, United Kingdom
Research Site, Peterborough PE3 9GZ, United Kingdom
Research Site, Chandler, Arizona 85224, United States
Research Site, Vancouver, British Columbia V5Z 4E6, Canada
Research Site, Anaheim, California 92801, United States
Research Site, Beverly Hills, California 90211, United States
Research Site, Concord, California 94520, United States
Research Site, Duarte, California 91010, United States
Research Site, Montebello, California 90640, United States
Research Site, San Francisco, California 94115, United States
Research Site, Sylmar, California 91342, United States
Research Site, Barcelona, Cataluña 08003, Spain
Research Site, L'Hospitalet de Llobregat, Cataluña 08907, Spain
Research Site, Sabadell, Cataluña 08208, Spain
Research Site, Stamford, Connecticut 06902, United States
Research Site, Boca Raton, Florida 33428, United States
Research Site, Boynton Beach, Florida 33435, United States
Research Site, Coral Springs, Florida 33065, United States
Research Site, Gainesville, Florida 32605, United States
Research Site, Lake Worth, Florida 33467, United States
Research Site, Atlanta, Georgia 30309, United States
Research Site, Marietta, Georgia 30060, United States
Research Site, Chicago, Illinois 60637, United States
Research Site, Lebanon, New Hampshire 03756, United States
Research Site, Denville, New Jersey 07834, United States
Research Site, Waratah, New South Wales 2298, Australia
Research Site, High Point, North Carolina 27262, United States
Research Site, Ottawa, Ontario K1H 8L6, Canada
Research Site, Sault Ste. Marie, Ontario P6B 0A8, Canada
Research Site, Toronto, Ontario M5G 2M9, Canada
Research Site, Hershey, Pennsylvania 17033, United States
Research Site, Pittsburgh, Pennsylvania 15213, United States
Research Site, Montreal, Quebec H1T 2M4, Canada
Research Site, Woodville South, South Australia 5011, Australia
Research Site, Memphis, Tennessee 38120, United States
Research Site, American Fork, Utah 84003, United States
Research Site, Footscray, Victoria 3011, Australia
Research Site, Geelong, Victoria 3220, Australia
Research Site, Malvern, Victoria 3144, Australia
Research Site, Tacoma, Washington 98405, United States
Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013 Mar;14(3):228-35. doi: 10.1016/S1470-2045(13)70026-3. Epub 2013 Feb 13.